A review of the challenges and proposals for improving patient access to advanced therapeutic medicinal products in 10 EU countries

RARE IMPACT Working Group
January 2020

Gene and cell therapies represent some of the most advanced treatments being employed in biomedical research to improve the length and quality of life of patients with rare and complex diseases. Patients’ access to these therapies has been hampered by both practical and technical challenges. RARE IMPACT is a collaboration of three not-for-profit organisations, two trade associations and 18 manufacturers of gene and cell therapies brought together by EURORDIS, a non-governmental patient-driven alliance of patient organisations. The group has collaborated on a series of reports to review the challenges and proposals for improving patient access to advanced therapy medicinal products (ATMPs) in 10 European countries:

Austria
Czech Republic
Denmark
England
France
Germany
Italy
Netherlands
Spain
Sweden